Epigenica AB has announced a distribution agreement with PrimeTech, a leading distributor of life science technologies in Japan.
According to a March 19th statement, the partnership will bring Epigenica's EpiFinder technologies to researchers and laboratories across the Japanese market.
Japan is home to one of the world's most advanced life science ecosystems, characterised by significant investment in genomics, biomarker discovery and translational research.
Through this collaboration, PrimeTech will distribute Epigenica’s EpiFinder kits and assist local researchers in utilising this technology for epigenetic analysis and biomarker discovery.
"Japan is a highly innovative market with world-leading research institutions and a strong interest in advanced omics technologies," said Mohamad Takwa, CEO and co-founder of Epigenica.
We are delighted to partner with PrimeTech to make EpiFinder more accessible to researchers in Japan and support new discoveries in areas such as cancer biology, ageing research and precision medicine.
PrimeTech has extensive experience supporting life science researchers and introducing innovative technologies to the Japanese market.
"We are very pleased to collaborate with Epigenica and introduce the EpiFinder technology to researchers in Japan," said Ryosuke Ogihara, CEO of PrimeTech.
The ability to generate epigenetic information at the scale that EpiFinder offers opens exciting opportunities for biomarker discovery and translational research.
Epigenica’s EpiFinder platform allows for high-throughput epigenetic profiling across various cell types and tissues, as well as the detection of epigenetic signals in blood through circulating nucleosomes.
The tool enables researchers to study gene regulation and discover new epigenetic biomarkers.
The firm added that the agreement marks a significant advancement in its international commercialisation strategy, further expanding access to its technologies in key research markets.